What drugs does INTRA-CELLULAR make?

INTRA-CELLULAR has 1 FDA-approved drugs including CAPLYTA.

What therapeutic areas does INTRA-CELLULAR focus on?

INTRA-CELLULAR focuses primarily on Neurology and Cardiovascular.

← Back

Data updated: Mar 10, 2026

INTRA-CELLULAR

NeurologyCardiovascular

Pharma

INTRA-CELLULAR is a pharmaceutical company focused on Neurology, Cardiovascular. Key products include CAPLYTA.

2019

Since

Drugs

Trials

Approved (2yr)

Key Drugs

CAPLYTA

lumateperone tosylate

CNS

5-HT2A 3 indications · 2019

Recent Activity

CAPLYTA 2025-11-05

Efficacy

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 92%

0 drugs Phase 3: 1 Phase 2: 3 Phase 1: 1

Cardiovascular 8%

0 drugs Phase 1: 1

Pipeline Strength ProEarly access

Competitors ProEarly access

GE HEALTHCARE specialty

Neurology, Cardiovascular

Novo Nordisk big-pharma

Cardiovascular, Neurology

LEDERLE big-pharma

Cardiovascular, Neurology

PAI HOLDINGS PHARM big-pharma

Neurology, Cardiovascular

VALIDUS PHARMS specialty

Cardiovascular, Neurology

INTRA-CELLULAR

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (1)

Active (1)

Discontinued (0)

Company Info